Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel-Reference-Cited by-同舟云学术

Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel

Published:2018-11 Issue:11 Volume:28 Page:245-250
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Ruiz-Pinto Sara,Martin Miguel,Pita Guillermo,Caronia Daniela,de la Torre-Montero Julio C.,Moreno Leticia T.,Moreno Fernando,García-Sáenz José Á.,Benítez Javier,González-Neira Anna

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics(clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference39 articles.

1. Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer;Arriola;Eur J Cancer Oxf Engl,2006

2. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer;Gradishar;Ann Oncol,2005

3. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer;Martin;Breast Cancer Res Treat,2011

4. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers;Tham;Breast Cancer Res Treat,2005

5. Neoadjuvant treatment of breast cancer;Thompson;Ann Oncol,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast cancer pharmacogenetics: a systematic review;Pharmacogenomics;2023-01

2. Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy;Cancers;2022-11-04

3. Single Nucleotide Polymorphisms as the Efficient Prognostic Markers in Breast Cancer;Current Cancer Drug Targets;2021-10